Detail akcie Viatris Rg-WI online

Business Summary: Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Viatris Inc revenues decreased 5% to $15.43B. Net income decreased 97% to $54.7M. Revenues reflect Developed markets segment decrease of 5% to $9.25B, JANZ segment decrease of 13% to $1.42B, Emerging Markets segment decrease of 2% to $2.55B, United States segment decrease of 10% to $3.55B, China (Country) segment decrease of 3% to $1.89B.